WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

WashU Expert: Pfizer deal marks the end of U.S. ability to stop corporate tax inversion

U.S. pharmaceutical giant Pfizer announced Nov. 23 a record-breaking $160 billion merger with Irish firm Allergan, the biggest merger to date involving the controversial strategy of tax inversion. The move marks the beginning of the end of the ability to stop corporate tax inversions under current tax rules, said Adam Rosenzweig, JD, professor of law and an expert on international tax law at Washington University in St. Louis.
What is confident pluralism?

What is confident pluralism?

How do we get back to forming meaningful relationships that can move toward common ground, despite our deep ideological differences? The answer lies in a confident pluralism, said John Inazu, an expert on law and religion.
View More Stories